Slash drug discovery timelines with GPT-Rosalind
The pharmaceutical industry has been stuck in a productivity rut for decades. We spend billions of dollars and ten years […]
Slash drug discovery timelines with GPT-Rosalind Read Post »
Sell Before the Drug Patent Expiration Cliff: A guide for Commercial & Market Access Vendors using anticipated Loss of Exclusivity dates to offer contracting strategy support before generic entry
The 36-Month Window Most Vendors Miss Every year, billions of dollars in brand pharmaceutical revenue disappear within months of patent
Authorized Generics: The Innovator’s Playbook for Diluting First-Filer Profits
The pharmaceutical industry’s most elegant competitive weapon is also its most misunderstood. When a brand-name drug manufacturer launches its own
Authorized Generics: The Innovator’s Playbook for Diluting First-Filer Profits Read Post »
Read the Clock Right: Mapping Regulatory Exclusivities for True Generic Drug Entry Timing
The Date That Actually Controls Generic Entry Walk into almost any pharmaceutical business development meeting, and the discussion of competitive
Win the Patent War Before the Drug Goes Generic: How Paragraph IV Challenges and Pay-for-Delay Settlements Decide Who Gets Paid — and Who Gets Blocked
The moment a pharmaceutical brand company files a new drug application with the FDA, a clock starts ticking. Somewhere across
Why Consumers Pay a “Trust Premium” for Branded Generics
How pharmaceutical companies engineer consumer psychology to extract billions from brand loyalty after patents expire — and what it means
Why Consumers Pay a “Trust Premium” for Branded Generics Read Post »
What AI Knows About Your Drug vs. Your Competitors
Pharmaceutical brand teams spend millions monitoring what doctors, patients, and payers say about their drugs. Most of that investment goes
What AI Knows About Your Drug vs. Your Competitors Read Post »
Read the Patent, Beat the Competition: The Intelligence Gap Most Pharma Teams Leave Open
Every pharmaceutical company files patents to protect its investment. Every one of those patents is a public document. And yet,
Read the Patent, Beat the Competition: The Intelligence Gap Most Pharma Teams Leave Open Read Post »
Two Systems, One Fight: How the Patent Dance and Orange Book Linkage Shape the $400 Billion Biologics War
The Fork in the Road That Determines Billions When a drug company files for FDA approval of a new medicine,
